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ABSTRACT 
Background/Purpose  
Population-based testing for BRCA1/2 mutations detects the high proportion of 
carriers not identified by cancer family-history (FH) based testing. We compare the 
cost-effectiveness of population-based BRCA testing with the standard FH-based 
approach in Ashkenazi-Jewish (AJ) women. 
Methods  
A decision-analytic model was developed to compare lifetime costs and effects 
amongst AJ women in the UK of BRCA founder-mutation testing amongst (a) all 
women in the population ≥30 years and (b) just those with a strong FH (≥10% 
mutation risk). The model that assumes BRCA carriers are offered risk-reducing 
salpingo-oophorectomy and annual MRI/mammography screening or risk-reducing 
mastectomy. Model probabilities utilize the GCaPPS trial/published literature to 
estimate total costs, effects in terms of Quality-Adjusted-Life-Years(QALYs), cancer 
incidence, incremental cost-effectiveness ratio(ICER) and population impact. Costs 
are reported at 2010 prices. Costs/outcomes were discounted at 3.5%. 
Deterministic/Probabilistic sensitivity analysis (PSA) evaluated model uncertainty.  
Results 
Compared to FH-based testing, population-screening saved 0.090 more life-years 
and 0.101 more QALYs resulting in 33 days gain in life-expectancy. Population-
screening was found to be cost saving with a baseline discounted ICER of -£2079/ 
QALY. Population-based screening lowered ovarian and breast cancer incidence by 
0.34% and 0.62%. Assuming 71% testing uptake, this leads to 276 fewer ovarian 
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and 508 fewer breast cancer cases. Overall, reduction in treatment costs led to a 
discounted cost-saving of £3.7 million. Deterministic sensitivity analysis and 94% of 
simulations on PSA (threshold £20,000) indicated that population-screening is cost-
effective compared with current NHS policy.  
 
Conclusion 
Population-based screening for BRCA-mutations is highly cost-effective compared to 
a FH-based approach in AJ women ≥30years.  
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INTRODUCTION 
 
Genetic testing for high-penetrance BRCA mutations is currently restricted to 
individuals from high-risk families fulfilling stringent family-history (FH) based criteria. 
However, a large proportion of BRCA-carriers do not fulfil the current threshold for 
genetic testing. We found that >50% of BRCA-carriers are missed by the FH-based 
approach, which is consistent with some earlier reports in which 40%-63%[1-3] of 
carriers in population cohorts and 50%-75% of carriers from cancer case series 
unselected for FH,[4-9] lacked a strong FH of cancer. New gene-sequencing 
technologies,[10] and the falling cost of genetic-testing will make it feasible to test 
large populations in the near future. This could lead to new approaches capable of 
detecting a larger proportion of carriers of high penetrance mutations and a change 
from the current FH-based approach. Systematic BRCA founder-mutation (FM) 
testing in a low risk Ashkenazi Jewish (AJ) population is acceptable and is not 
associated with differences in short term psychological or quality-of-life outcomes 
compared to a FH-based approach [11]. The AJ population could be the first 
population for whom population based testing is feasible. 
 
A health-economic evaluation is essential for an overall assessment of the balance 
of costs and health benefits in the context of setting public health policy for genetic 
testing of high penetrance cancer gene mutations. Decision analytical modelling 
compares the expected costs and consequences of decision options by synthesizing 
information from multiple sources and applying mathematical techniques, usually 
with computer software [12]. The current clinical approach which uses high-risk 
families for case identification is more cost-effective than no genetic screening with a 
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cost-effectiveness ratio (CER) of 4,294 euros/life-year gained reported [13]. In 
addition, preventive surgery is more cost-effective than screening in known BRCA 
and mismatch repair (MMR) gene carriers.[14-16] However, health-economic data 
using truly population-based ascertainment are limited.  There is only one cost-utility 
analysis comparing population-based screening with no screening in the AJ 
population [17], which found that screening would prevent 2811 ovarian cancers in 
the USA, for a (discounted) program cost of $8300/quality-adjusted life-year (QALY). 
However, to date, the cost-effectiveness of a population-based approach has not 
been compared with a FH-based approach. Genetic Cancer Prediction through 
Population Screening (GCaPPS) is a randomized trial (ISRCTN73338115) 
comparing outcomes of population and FH-based approaches for genetic-testing in 
UK AJ women. In order to provide policy makers with the best available evidence, 
we use data from the GCaPPS trial to describe a decision analysis model comparing 
both population and FH-based approaches for genetic-testing in AJ women.   
 
METHODS 
 
A decision analytic model (Figure-1) was developed to compare the lifetime costs 
and effects of genetically screening all UK AJ women ≥30 years for BRCA FM 
compared with the current practice of screening using FH-based criteria (≥10% 
mutation risk)  (Supplementary Table 1, available online). The model assumes that 
all women in the population-screening arm and only those with a strong FH in the FH 
arm are offered genetic counseling and genetic testing. A 71% uptake rate of genetic 
testing (estimated from the GCaPPS study) was incorporated into the model. 
Genetic testing involved analysis for the three BRCA FM associated with Jewish 
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descent in a National Health Service (NHS) genetics laboratory. In line with current 
guidelines, [18, 19] women testing positive were offered risk reducing salpingo-
oophorectomy (RRSO) to reduce their ovarian cancer risk [20, 21] and 
MRI/mammography screening or risk-reducing mastectomy (RRM) [22] to reduce 
their breast cancer risk. Use of a selective estrogen receptor modulator (SERM) for 
breast cancer chemoprevention [23] was also included in the model as part of a 
sensitivity analysis, but ovarian cancer screening was excluded, as its clinical value 
remains uncertain.[24] In line with guidelines on the reference case for economic 
evaluation from the National Institute of Health and Clinical Excellence(NICE), all 
costs and outcomes were discounted at 3.5%.[25]  
 
Probabilities 
All pathway probabilities for the model are presented and explained in Table-1. A 
one way sensitivity analysis involved rerunning the model at both lower and upper 
values/limits of the 95%CI or range of all probability parameters (Table-1) used in the 
model (Figures 2,3). Cancer incidence was estimated by summing the probabilities 
of pathways ending in ovarian or breast cancer. The current estimated UK population 
of AJ women is 114,400.[26, 27] The total population impact was estimated by 
multiplying the results per woman by 81,224 (0.71*114,400). Additionally, the effect if 
all 114,400 women underwent testing is also calculated 
 
Costs 
All costs are reported at 2010 prices and where required have been converted using 
the Hospital and Community Health Service Index.[28] These are described in detail 
in Table 2.  
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Life years 
Life expectancy for women not developing cancer (53 years) was based on life-
tables from the Office of National Statistics.[29] The mean age for breast/ovarian 
cancer onset was 41.7/51.5 years for BRCA1 and 45.6/58.9 years for BRCA2 AJ 
women, respectively.[30] To simplify the analysis we used average ages for breast 
(43.5 years) and ovarian cancer (54.9 years) onset for BRCA1/BRCA2 carriers, 
obtained by assigning weights to the individual ages of onset for the relative 
population prevalence of BRCA1 and BRCA2 FM ((1.32*AgeBRCA1)/2.45 + 
(1.13*AgeBRCA2)/2.45)). The mean ages for sporadic breast and ovarian cancer in AJ-
women were 57 years and 63years, respectively.[31-33] In the absence of AJ 
specific survival data, five-year survival rates were assumed to be the same as the 
general UK population.[34] This model incorporates potential survival differences 
between BRCA1, BRCA2 and sporadic ovarian cancers.[35, 36] No statistically 
significant survival difference between BRCA and sporadic breast cancers has been 
reported.[37, 38]  For ovarian cancer the 5 year survival for BRCA1 is 44% (95%CI: 
40%-48%) and for BRCA2 52% (95%CI:46%-58%),[35] giving a composite 5 year 
survival for BRCA1+BRCA2 (weighted by BRCA1 and BRCA2 prevalence) of 0.477 
((0.44*1.32/2.45)+(0.52*1.13/2.45)). After five years survival, the probability of death 
was assumed to be the same as the general population.  
 
Quality adjusted life years (QALYs) 
QALY is a measurement which expresses changes in length of life, while at the 
same time incorporating reductions in quality-of-life. Calculation of QALYs requires 
knowledge of quality-of-life adjustment or utility-weights for each health state in the 
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model. ‘Utility-weights’ are an indication of an individual’s preference for specific 
health states where ‘1’=perfect health and ‘0’=death. QALY=Survival in life-years x 
Utility-weight. No studies that measured utility-scores directly for women undergoing 
RRSO were identified. A Dutch study found no measurable impact on generic 
quality-of-life in high-risk women undergoing RRSO.[39]   Therefore, we did not 
include a utility decrement for RRSO in our analysis. Havrilesky [40] reported 
detailed utility estimates related to various health states following ovarian cancer 
treatment using visual analogue scale and time-trade-off (TTO) methods. As visual 
scales for comparing health state preferences are subject to inherent biases and are 
generally less accurate,[41] we have utilized the TTO scores. We assumed 70% of 
women present with ovarian cancer at advanced stages,[42, 43] with a lower utility-
score for a new diagnosis at 0.55 (sd=0.29), while the remainder presenting at early 
stages have a higher utility score of 0.81 (sd=0.26). The end-stage of life utility-score 
where ovarian cancer patients did not survive the next year=0.16 (sd=0.25). Of those 
that survived initial chemotherapy the chance of recurrence with early disease was 
10.5% annually,[44] and with advanced disease this would be 20.6%.[42] For women 
with recurrent disease the mean utility value was 0.5 (range=0.4-0.61) and for 
women in remission the utility-value was 0.83 (sd=0.25).[40]  
 
Of general population breast cancer, 10% is non-invasive/DCIS; 90% is invasive; 
95% of invasive cancer is early-&-locally advanced (41%=Stage-1, 45%=stage-2, 
9%=stage-3[45-48]) and 5% is advanced (stage 4)[45-47]. In BRCA carriers, 20% of 
cancers are DCIS and 80% invasive (61%=stage1).[18, 49] Utility weights for breast 
cancer were assumed as follows: advanced breast cancer 0.65, early or locally 
advanced breast cancer 0.71, remission 0.81, recurrence 0.45 and have been 
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obtained from NICE guidelines.[50, 51]   For those who survived initial 
chemotherapy, the chance of breast cancer recurrence/progression with early/locally 
advanced disease was 35% [47] and for recurrence with advanced disease, 
66%.[52] 
Analysis 
For each branch of the decision-model, the probability of being in each branch was 
calculated by multiplying together the path probabilities. The total costs and effects in 
terms of life years and QALYs were then estimated by weighting the values for each 
branch by the probability of being in each branch. The incremental cost-effectiveness 
ratio (ICER) was estimated by dividing the difference in cost by the difference in 
effect. ICER= (Cost A–Cost B)/(Effect A–Effect B). By comparing this ICER with the 
cost-effectiveness threshold used by NICE (£20,000-£30,000/QALY),[53] it was 
possible to determine whether or not population-screening for all women was cost-
effective compared with FH-based testing. To explore uncertainty in the results and 
robustness of the model, a one-way sensitivity analysis was undertaken by varying 
each parameter in the model and then re-running the model to assess the impact on 
overall results. Probabilities and utility-scores were varied according to their 95% 
confidence-intervals/ range, where available, or by +/-10%, and costs were varied by 
+/-30%. In addition to the one-way sensitivity results, a probabilistic sensitivity 
analysis (PSA) was undertaken as recommended by NICE methods guidance.[25, 
54] Any variation in model parameters/variables is likely to occur in parallel rather 
than independently of each other. In the PSA all variables are varied simultaneously 
across their distributions to further explore model uncertainty. We assigned costs a 
gamma distribution, probabilities a beta distribution, and utilities a log-normal 
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distribution as suggested in the literature.[55] The results of 1000 simulations were 
plotted on a cost-effectiveness acceptability curve showing the proportion of 
simulations that indicated that the intervention was cost-effective at different 
willingness to pay thresholds.  Other scenarios also explored included: (a) breast 
cancer prophylaxis with SERMs (Tamoxifen/Raloxifene) in BRCA carriers[19, 23]; 
and (b) women opting for genetic testing at 50 years (average age of menopause) 
with a median age for RRSO and RRM at 54 years (just below the weighted average 
age of ovarian cancer onset in BRCA1/BRCA2 carriers) .  
 
RESULTS 
 
The discounted and undiscounted lifetime costs, life-years and QALYs for each 
branch in the decision model are given in Table-3. Overall a population-screening 
approach saved more life-years (0.090)  and QALYs (0.101) than a FH-based 
approach. This difference equated to 33 days gain in life expectancy for AJ women 
using a population-screening strategy compared to a FH-based one. Discounted 
results show a smaller overall gain in life-years and QALYs and overall cost 
difference, as discounting adjusts costs and outcomes that occur in the future and 
the cost savings generated through prevention of future ovarian cancer cases is 
valued less. The baseline discounted ICER was -£2079/QALY indicating that 
population based screening not only saves more QALYs but is also cost saving and 
is highly cost-effective in AJ women. This is well below the NICE threshold of 
£20,000-£30,000/QALY. Population-based screening also lowered ovarian cancer 
incidence by 0.34% (from 2.49% to 2.15%) and lowered breast cancer incidence by 
0.62% (from 13.31% to 12.69%). Assuming that 71% of the estimated 114,000 AJ 
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women in the UK [26, 27] undergo testing, the overall impact of a population-based 
strategy is a reduction in ovarian cancer and breast cancer by 276 and 508 cases, 
respectively, at a discounted cost saving of £3.7 million. Should the entire population 
undergo testing, the number of cancers potentially prevented would increase to 388 
for ovarian and 715 for breast cancers at a discounted cost saving of £5.2 million. 
 
The results of the one-way sensitivity analysis (Figures 2,3) indicate that the 
upper/lower utility-values, costs, penetrance estimates, and rate of uptake of 
preventive/risk-reducing surgery  have little influence on the overall results, and the 
model is cost saving at both upper and lower limits of these variables. However, the 
model is highly sensitive to the overall BRCA prevalence and BRCA prevalence in 
FH-negative women (Figure 2). At the lower limits of overall BRCA prevalence and 
BRCA prevalence in FH-positive individuals the intervention was still just cost saving 
at -£183/QALY and -£631/QALY, respectively. At the lowest value for BRCA 
prevalence in FH-negative women, the ICER= £3877/QALY, well under the NICE 
threshold of £20,000-£30,000/QALY  indicating that population-screening was still 
cost-effective, but no longer cost saving. At the highest BRCA prevalence rates in 
FH-positive and FH-negative women, the intervention was both more effective and 
cost-saving. 
 
 The probabilistic sensitivity analysis results (Figure 4) shows that at a threshold of 
£20,000 94% of simulations indicate that population-screening in AJ women is a 
cost-effective intervention compared with current NHS policy. A scenario 
incorporating breast cancer prophylaxis with Tamoxifen (pre-menopausal)/ 
Raloxifene (post-menopausal) in BRCA carriers as recently recommended by NICE 
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[19] achieved a greater saving of cost/QALY= -£2472 for population-based screening 
compared to FH-based testing. A further scenario where unaffected women aged 50 
years were screened for BRCA mutations (with a median age for RRSO and RRM= 
54 years), also achieved a higher saving of cost/QALY= -£2946.   
 
DISCUSSION  
 
According to NICE, a cost-effectiveness analysis comparing the relative health-
outcomes and costs of interventions is the preferred form of economic evaluation, 
and QALY is the most suitable determinant of health benefit, reflecting both mortality 
and health related quality-of-life effects.[25] Value-based judgements are used to 
assign an appropriate price for health outcomes. This analysis focused on whether 
the cost differential between different interventions/strategies is worthwhile in terms 
of changes in health outcomes. Our decision-analysis model addressed the topical 
issue of cost-effectiveness of a new population-based BRCA-testing strategy in AJ 
women made possible by identification of AJ founder mutations and advances in the 
efficiency/cost of technology for mutation detection. Our finding that a population-
screening program implemented in UK AJ women >30 years will be cost saving 
compared to the current FH-based one has important implications for clinical care, 
population/public health, and for health care providers and commissioners. There is 
potential within the UK for reduction of the number of ovarian cancers by 276 and 
breast cancers by 508, combined with overall cost savings of £3.7 million. Should the 
entire relevant UK population undergo testing, the number of cancers potentially 
prevented would increase to 388 for ovarian and 715 for breast cancer at a 
discounted cost saving of £5.2 million. This compares favorably with a number of 
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interventions routinely used in clinical practice, which whilst saving lives cost more. 
For instance, the ICER for breast screening in BRCA1/BRCA2 carriers from 35-49 
years recommended by NICE [56]=£11,700(MRI-alone) or £15,300 
(MRI+mammography) per case of cancer detected.[57] The ICER for paclitaxel and 
cisplatin for primary treatment of ovarian cancer ranges between $6600-$22,000/life-
year gained.[58, 59]  
 
This is the first report comparing cost-effectiveness of population-screening for 
founder mutations of BRCA1/2 with the current standard of care. Our analysis 
incorporates impact on both breast and ovarian cancer risk and fulfills various 
requirements suggested by NICE for health-economic decision making. The ‘time-
horizon’ in our analysis is long enough to reflect important differences in costs and 
outcomes.[25] We use current best practice as a comparator, QALYs to measure 
health-outcomes, a 3.5% discount rate on costs and health outcomes and, as far as 
possible, directly obtained population-based data for parameters in the analysis.[25] 
This is the first model to incorporate BRCA prevalence in FH-negative individuals, 
and probabilities used in the model are consistent with other reports in the 
literature.[2, 60] A comparison of population-screening for BRCA-carriers vs. no 
screening reported an ICER=$8300/QALY.[17] This higher value compared to the 
cost savings in our study could be attributable to our lower costs of testing, higher 
health care costs in the USA compared to the UK and the beneficial impact of breast 
cancer prevention found in our study but not evaluated by the earlier study.[17] 
Another advantage of our model is that it also includes genetic counseling costs, 
which would be a key component of any population-based testing strategy. This 
approach facilitates reflection of positive/negative consequences of genetic-testing 
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and permits participants to make informed decisions based on their own values and 
opinions. In order to minimize over-estimating benefits of population-based 
screening, we have been conservative in our use of ovarian and breast cancer 
penetrance estimates (corrected for ascertainment) [61] as well as our costs for 
ovarian and breast cancer diagnosis and treatment, by including a minimal subset of 
baseline costs. We did not include all costs for additional investigations, treatment of 
recurrence or management of complications.  
 
The deterministic sensitivity analysis permitted scrutiny of model outcomes and 
identification of variables that exert the most influence (Figures-2,3). The 95% 
confidence-limits for probabilities explored in our sensitivity analysis were quite wide, 
adding to the strength of the results. The lack of statistically significant effect on 
outcome despite 30% variation in costs indicates that costs of counseling, treatment, 
and prevention are less important in influencing the overall results. BRCA prevalence 
rates (P1, P8) emerged as the key variables of influence given the higher model 
sensitivity to uncertainties around these values (Figure 2). That the model remains 
largely cost saving despite probabilities varying widely is reassuring. Even at low 
prevalence rates in FH-positive or FH-negative individuals, population testing 
remained cost-effective compared to the NICE threshold of £20,000-
£30,000/QALY[53] . Though we used a RRSO risk-reduction estimate (0.96) based 
on the residual-risk of PPC,[20] a lower rate of 0.8[21] assessed in the sensitivity 
analysis showed it was still cost saving. RRSO rates vary with time, menopausal 
status, age, and parity.[62] It is encouraging that even at low (0.3) RRSO rates, the 
model remains cost saving (Figure 2). The PSA undertaken adds to the robustness 
of our results and has been recommended by decision making bodies.[25] It permits 
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simultaneous variation in probabilities of all parameters to fully characterize  
uncertainties in the model and its effect on overall results. That 94% of simulations 
on PSA were cost-effective reconfirms the health-economic benefit of a population-
based approach to genetic testing.  
 
Our model is limited by a number of assumptions. It does not incorporate any 
potential reduction in QALY following RRSO. Although RRSO is associated with 
worse menopausal symptoms and sexual functioning compared to women 
undergoing screening, no difference in generic quality-of-life has been reported.[39, 
63, 64] RRSO has also been linked with a higher risk of cardiovascular disease [65, 
66] and osteoporosis. We felt that these downsides in premenopausal women may 
be balanced by the decrease in vasomotor symptoms, cardiovascular sequelae and 
improved sexual functioning and osteo-protection seen with hormone-replacement-
therapy (HRT), [63, 65, 67-69] as well as the reduction in cancer worry, perceived 
risk, and high overall satisfaction observed following RRSO.[39, 63] RRSO also 
halves the risk of subsequent breast cancer in premenopausal women,[21] and 
available evidence suggests that HRT does not alter the significant benefit of 
reduction in breast cancer risk obtained from bilateral oophorectomy.[70]   
 
Of BRCA carriers, 21-67% undergo risk-reducing mastectomy.[71-73] Addition of 
risk-reducing mastectomy or screening to RRSO further increases life expectancy in 
BRCA carriers.[74] Our model incorporates the impact of breast screening already 
prevalent in the  UK and includes the benefits of reduction in breast cancer risk 
obtained from RRSO [21] and risk-reducing mastectomy (RRM) [22] .  Our analysis 
does not incorporate any potential reduction in QALY following RRM. Although a 
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negative impact on sexual pleasure and body image has been reported, no 
difference over time in sexual habit, discomfort, or activity was documented.[75] Lack 
of adverse effects on anxiety, depression, and health related quality-of-life over time 
has also been reported.[18, 75, 76] Additionally, any negative effects of RRM could 
be balanced by findings of significant decreases in anxiety scores, improved social 
activity,[75] reports of a majority of women finding RRM results to be consistent with 
their expectations, and high satisfaction with overall cosmetic results.[76-79]  
 
Although it can be hypothesized that FH positive women may be more likely to adapt 
to their increased risk while FH negative women have less of an opportunity to 
consider/adapt to these issues before being tested, we did not find FH to significantly 
affect QoL outcomes in our GCaPPS trial. Not all of those undergoing genetic 
counseling will opt for genetic testing, and a reduced genetic-testing uptake rate is 
built into the model costs. A total of 1034(71%) of 1450 people who made a genetic 
counseling appointment in the GCaPPS study underwent BRCA testing. This equals 
1034(89%) of 1168 who attended pre-test counseling. FH did not 
significantlyinfluence uptake of testing in our population-based trial; hence, uptake 
using either FH or population approaches in our decision-model is assumed to be 
similar (71%).  This estimate lies well within the range of genetic testing rates 
(varying from 66%-90%)[80-83] reported by previous studies of varying 
ascertainment and sizes.  
 
The intermarriage rate in the Jewish community is likely to lead to a fall in BRCA 
founder-mutation prevalence. 25% Jewish marriages in the UK and 44% in the USA 
are to non-Jews, although only 50% of the population is married. Hence, overall, the 
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impact of this is unlikely to affect >25% of the population. Assuming a BRCA-
prevalence of 2.5% for 75%, and 1% for 25% of the population, the overall 
population BRCA-prevalence will be ~2.1%. Even if BRCA prevalence=1% for 50% 
of the population, the overall population prevalence will be ~1.75%. These extremes 
are well within the 95% confidence intervals accounted for in our sensitivity analysis, 
which shows the model to be cost-effective. 
 
Implementation of any national screening program has many challenges and raises 
important issues of logistics and quality control. It also requires raising public (and 
health professional) awareness/education, community engagement and information 
dissemination via media campaigns, which have an added cost. In the UK, screening 
programs are centrally coordinated by the national screening committee, with fail 
safe procedures and involve close co-ordination with GP/primary care and public 
health physicians. In addition there is need for clearly defined downstream 
secondary and tertiary care pathways, developed in close co-ordination with clinical 
genetics teams, breast surgeons, gynecologists and others responsible for the 
management of women found to be at high risk. While these pathways exist for high 
risk women, they would need to be expanded prior to program implementation. It 
would not be sensible or feasible for all women to undergo pre-test counseling in 
tertiary high-risk cancer genetics clinics within a hospital setting, so a community 
based approach would need to be explored. We have demonstrated that successful 
recruitment to such a population-based program for pre-test counseling and BRCA-
testing outside a hospital setting is possible using a community/high-street based 
model. More efficient, acceptable, and cost-effective ways of delivering information 
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on genetic risk will be needed for any population-based testing program to become a 
reality and this area should be the focus of further research.  
 
Health-economic assessments are critical for determining the appropriateness of 
resource allocation for cost intensive population-based interventions. Rising health 
care costs and the ever increasing price of new ovarian/breast cancer treatments 
and drug therapies in a challenging economic environment further magnify the 
importance of newer cost-effective preventive strategies. An important advantage of 
population-screening is the ability to identify BRCA carriers without a strong FH of 
cancer undetectable by a FH-based approach. This translates to 2322 additional UK 
AJ-women (population prevalence=2.03% (95%CI:1.14%,3.32%)) who may benefit 
from access to screening/preventive options. The lack of statistically significant 
difference in short-term outcomes of anxiety, depression, quality-of-life, health-
anxiety and overall impact of genetic testing between FH and population-based 
approaches reconfirms that population-based genetic testing in the majority of 
Jewish people does not harm quality-of-life or psychological well-being, or lead to 
excessive health concerns.[11]  
 
The high cost-effectiveness of population-based testing in AJ-women demonstrated 
in this analysis combined with the above findings should justify a change in the 
current paradigm which is limited to a FH-based approach to BRCA-testing in the AJ 
population. We conclude that introduction of systematic population testing for AJ 
BRCA1/2 founder mutations could save both lives and financial resources. Finally, 
we emphasise that the results from our analysis are related to population based 
BRCA testing in AJ women and cannot be directly extrapolated to non-AJ 
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populations with lower prevalence rates for BRCA1/2 mutations. Nevertheless, as 
the cost of testing falls and the acceptance/understanding of this type of health 
intervention evolves in our societies, it is likely to become an increasingly important 
area for research and evaluation.  
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 Table 1: Probabilities of different pathways in the model 
Proba
bility  Value 
(95%CI) 
[Range] Description  Source  
P1 0.0245 (0.0131-0.0416) Population prevalence of BRCA FM GCaPPS 
P2 0.52 (0.39-0.67) Probability that carrier will undergo RRM Evans[71]   
P3 0.96 [0.8-0.96] Reduction in risk of ovarian cancer from RRSO 
Finch[20] , 
Rebbeck[21]  
P4 0.2987 (0.2485-0.3539) 
Probability that carrier 
without RRSO will get 
ovarian cancer 
Chen[61] 
P5 0.0185 (0.0005-0.0989) Probability that a non-carrier will get ovarian cancer CRUK[84] 
P6 0.1238 (0.1043-0.1454) Probability of having a positive FH GCaPPS 
P7 0.0938 (0.0637-0.1763) BRCA prevalence in FH positive  individuals GCaPPS 
P8  0.0203 (0.0114-0.0332) BRCA prevalence in FH negative  individuals GCaPPS 
P9 0.91 (0.62-0.98) 
Reduction in breast cancer  
risk from RRM without 
RRSO 
Rebbeck[22] 
P10 0.53 (0.44-0.62) 
Probability that carrier 
without RRM will get breast 
cancer  
Chen[61] 
P11 0.13 [0.11-0.14] 
Probability that a non-carrier 
will get breast cancer with 
screening 
 
CRUK[46], 
ONS[85] 
P12 0.55 (0.30-0.75) Probability that carrier will follow-up with RRSO Manchanda[62] 
P13 0.49 (0.37-0.65) Reduction in risk of breast cancer from RRSO alone Rebbeck[21]  
P14 0.95 (0.78-0.99) Reduction in risk of breast cancer from RRM with RRSO Rebbeck[22] 
95%CI- 95% confidence interval, FH- family history, FM- founder mutations, GCaPPS- 
Genetic Cancer Prediction through Population Screening study; RRSO- risk reducing 
salpingo-oophorectomy, RRM: Risk reducing Mastectomy 
Explanation: 
P1: The probability of carrying a BRCA FM in the AJ population (p1= 0.0245) is taken from 
the GCaPPS study as it provides UK based data and is consistent with reports from other 
countries.[2, 86]  
P2: The probability that BRCA1/2 carrier will undergo RRM is taken is taken from an 
analysis of UK BRCA1/2 carriers by Evans et al 2009. A composite uptake rate (p2=0.52) 
for BRCA1 (60% RRM rate) and BRCA2 (43% RRM rate) carriers  weighted for the relative 
prevalence of BRCA1 and BRCA2 FM found in the London AJ population was 
computed.[71] 
P3: The reduction in ovarian cancer risk obtained from RRSO (p3= 0.96) is taken from 
previous studies which report a 4% residual-risk of primary peritoneal cancer following 
RRSO.[20]  
P4: A wide range of ovarian cancer risks have been reported for BRCA carriers, with higher 
penetrance estimates found in carriers ascertained from high-risk families with multiple 
cancer cases.[87] Our analysis uses ovarian cancer penetrance figures (40% for BRCA1, 
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18% for BRCA2) from a meta-analysis, corrected for ascertainment.[61] To simplify the 
analysis we have used a composite risk for BRCA1 and BRCA2 carriers (p4= 0.2987) 
weighted for the relative prevalence of BRCA1 and BRCA2 FM found in the London AJ 
population. The BRCA1 population prevalence is 0.0132 and BRCA2 population prevalence 
is 0.0113 (GCaPPS study). The overall risk of ovarian cancer in BRCA carriers is calculated 
as ((0.0132*0.4)/2.45 + (0.0113*0.18)/2.45). 
P5: The risk of ovarian cancer in a low-risk population (p5= 0.0185) is obtained from 
Cancer Research UK.[84]  
P6: The probability of having a strong FH of cancer fulfilling the current clinical criteria (FH-
positive) is obtained from the population based GCaPPS study (p6= 0.1238 or 128/1034).  
P7, P8: The BRCA prevalence in FH-positive (p7=0.09375) and FH-negative (p8=0.0203) 
individuals is also obtained from the GCaPPS study where (12/128) BRCA carriers 
detected were FH-positive and (15/740) were FH-negative. 
P9: Reduction in breast cancer risk from RRM in BRCA carriers not undergoing RRSO is 
taken from the PROSE study data by Rebbeck et al, JCO 2004.[22] 
P10: The breast cancer penetrance for BRCA carriers (57% for BRCA1 and 49% for 
BRCA2) is taken from a meta-analysis, corrected for ascertainment.[61] To simplify the 
analysis we have used a composite risk for BRCA1 and BRCA2 carriers (P10= 0.53) 
weighted for the relative prevalence of BRCA1 and BRCA2 FM found in the London AJ 
population. The BRCA1 population prevalence is 0.0132 and BRCA2 population prevalence 
is 0.0113 (GCaPPS study). The overall risk of breast cancer in BRCA carriers is calculated 
as ((0.0132*0.57)/2.45 + (0.0113*0.49)/2.45). 
P11: The risk of breast cancer in a low risk population is taken from Cancer Research UK 
and UK Office for National Statistics data.[46, 85] 
P12: Undergoing RRSO can be a complex decision making process and RRSO rates 
ranging from 0.3 to 0.75 have been reported in the literature.[62, 71, 72, 88] We have used 
the RRSO rate recently reported in high-risk women from London (p2= 0.55), as it reflects 
the views of carriers from a London population and is within the range reported in the 
literature.[62] 
P13: The reduction in breast cancer risk in pre-menopausal women undergoing RRSO is 
taken from a meta-analysis by Rebbeck et al.[21] 
P14: Reduction in breast cancer risk from RRM in BRCA carriers undergoing RRSO is 
taken from the PROSE study data by Rebbeck et al, JCO 2004.[22] 
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Table 2: Summary of costs used in model (2010 prices)* 
Item Cost (£) Source 
Cost of genetic testing 50 GCaPPS 
Cost of counseling  33 GCaPPS, PSSRU Unit costs of Health and Social Care[89] 
Cost of RRSO (and HRT) 2222 NHS Reference costs[90], BNF[91]    
Cost of ovarian cancer 
diagnosis and initial 
treatment 
15,753 NHS Reference costs[90], NICE guideline[92] 
Yearly cost of ovarian cancer 
treatment and follow-up: 
years 1-2 
612 NHS Reference costs[90], NICE guideline[92] 
Yearly cost of ovarian cancer 
treatment  and follow-up: 
years 3-5 
262 NHS Reference costs[90], NICE guideline[92] 
Terminal care cost with 
ovarian cancer 14,716 National Audit office[93] 
Cost of breast cancer 
screening general  330 
Robertson 2011[94], NHS reference 
cost[90] 
Cost of breast cancer 
screening BRCA carriers  
5983 
 
NHS Reference costs[90], NICE guideline 
Famial breast cancer[19]  
Cost of RRM  3222 NHS Reference costs[90], weighted for 21% complication rate[18, 95]  
Cost of breast cancer 
treatment 
15039 
NHS Reference costs[90], NICE guideline 
Advanced breast cancer[50], NICE 
guidelines Early and locally advanced 
breast cancer[96]  
Yearly cost of breast cancer  
follow-up and adjuvant 
treatment if any (e.g. 
Tamoxifen): years 1-5 
1914 
BNF[91], Robertson 2011[94], NHS 
Reference costs[90],  
NICE guidelines Early and locally 
advanced breast cancer[96]  
NICE guideline Advanced breast 
cancer[50]   
National Costing report. Implementing 
NICE guidance 2009[47] 
 
 
*All costs were varied by +/-30% in one way sensitivity analysis 
BNF- British National Formulary, GCaPPS- Genetic Cancer Prediction through Population 
Screening study, HRT- hormone replacement therapy, NHS- National Health Service, NICE-
National Institutes for Health and Clinical Excellence, PSSRU- Personal Social Services 
Research Unit, RRSO- risk reducing salpingo-oophorectomy, RRM- risk reducing 
mastectomy, UK- United Kingdom 
Explanation† 
Cost of genetic counseling/testing: based on pre-test counseling time (45 minutes), 71% 
genetic testing uptake (GCaPPS study), and national unit cost assumed for genetic 
counseling= £44/hr of client contact from PSSRU Unit costs of Health and Social Care 
2010.[89, 97]  
RRSO costs: based on national reference costs for an upper genital tract 
laparoscopic/endoscopic intermediate procedure.[90] Costs of HRT (from BNF[91]) assumes 
HRT is given from average age of RRSO to the average age of menopause (51 years).  
Ovarian Cancer Costs: 
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Costs for ovarian cancer diagnosis and treatment: derived from national reference costs and 
a recent ovarian cancer guideline from NICE.[90, 92] We assumed cost of diagnosis includes 
a pelvic examination, ultrasound scan, CA125 test, CT scan, percutaneous biopsy and 
peritoneal cytology.  
The cost of treatment included the reference cost for a lower and upper genital tract very 
complex major procedure and administration of chemotherapy based on 6 cycles of 
carboplatin and paclitaxel treatment. It was assumed that in years-1 and -2 treated survivors 
would have a further three consultant visits, a CT scan and 4 CA125 tests each year. In 
years 3 to 5 post-surgery it was assumed that survivors would have 2 consultant visits and 2 
CA125 tests. We were conservative in our cost-estimates and did not include costs for 
additional investigations, treatment of recurrence or management of complications in the 
analysis.  
Costs for terminal care for ovarian cancer were derived from end-of-life costs for cancer 
patients based on a report from the National Audit Office, UK.[93]  
In line with NICE recommendations future healthcare costs not associated with ovarian 
cancer were not considered.[25] 
Breast Cancer Costs 
Breast Cancer diagnosis & treatment costs: derived predominantly from: ‘National costing 
report- Implementing NICE guidance (Feb 2009)’ which provides estimates of the national 
cost impact arising from implementation of NICE guidelines for diagnosis and treatment of 
early/locally advanced breast cancer and advanced breast cancer in England, UK[47]; from 
UK Department of Health NHS reference costs 2010-2011[90]; the BNF[91] and other 
relevant NICE guidelines on breast cancer care in general and high risk populations[19, 50, 
96]. 
Cost of breast cancer screening: assumes for non-carriers routine mammography (8 
mammograms between 50-70 years) as per UK NHS breast cancer screening program.[98] 
Cost of breast screening for BRCA carriers is based on annual mammogram from 40-69 
years and annual MRI from 30-49 years  as per NICE guidelines for familial breast 
cancer.[19] 
Cost of RRM: obtained from NHS reference costs[90] weighted for a 21% complication 
rate.[18, 95].  
Cost of breast cancer treatment: In the general population 10% breast cancer is non-invasive 
DCIS; 90% breast cancer is invasive; 95% of invasive breast cancer is early and locally 
advanced (41% Stage-1, 45% stage-2, 9% stage-3[45-48]); 5% of invasive breast cancer is 
advanced breast cancer (stage 4)[45-47]; 35% of early & locally advanced breast cancer will 
progress to advanced breast cancer (NICE costing report, 2009).[47] In BRCA carriers, 20% 
of cancers are DCIS and 80% invasive (61% stage1).[18, 49] 
The cost of diagnosis includes clinical examination, mammogram, ultrasound & biopsy. 
Mean prevalence of Axillary lymph node metastasis in early invasive breast cancer is 31.4% 
(systematic reviews within the NICE breast cancer guideline[96] and breast cancer clinical 
outcome measures (BCCOM) project[99]). 30% node positive rate is assumed for BRCA 
breast cancer (based on screening studies in familial breast cancer, breast cancer case 
series and Early Breast Cancer Trialists’ Collaborative Group data).[49, 100-103] 
Cost of Sentinel lymph node biopsy (SLNB): from NICE national costing report.[47] SLNB for 
staging axilla for early invasive breast cancer and no evidence of lymph node involvement on 
Ultrasound (US)/ negative US-guided biopsy (73% of invasive cancers). 
Cost of axillary lymph node dissection (ALND): assumed to be 25% of cost of breast surgery 
as per NICE guideline development group recommendation,[47] undertaken for lymph node 
positive cancers (31% early & locally advanced invasive cancers).[47, 96]  
Breast Surgery Costs: This includes, costs of breast conserving surgery (assumed for all 
non-invasive cancers, and 75% of early/locally advanced (stage 1-3) invasive cancers); and 
costs of mastectomy with reconstruction (for 25% early/locally advanced cancers). Costs are 
obtained from the national NHS reference costs.[90] 
Radiotherapy and Chemotherapy: Invasive breast cancers who are not low risk[99, 104, 105] 
receive adjuvant treatment in line with NICE guidelines. Costs include, radiotherapy costs for 
60% of early invasive/locally advanced, radiotherapy and chemotherapy costs for 40% early 
invasive/locally advanced and chemotherapy costs for all advanced cancers. Radiotherapy 
costs include planning and 40Gy, 15# over 3 weeks (NICE guidelines[96]) or palliative 
treatment, taken form national NHS reference costs.[90] Chemotherapy costs (based on 
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polychemotherapy)[100] include administration costs, costs of 1st and 2nd line therapy and 
toxicity from NICE guidelines.[47, 50] 
All costs are adjusted for BRCA breast cancers for difference in stage at presentation & 20% 
cancers being non-invasive.  
70% general population invasive breast cancers are ER positive; 15% early invasive breast 
cancers and 25% advanced breast cancers are HER2 positive[50, 96]. 27% BRCA1 and 
67% BRCA2 breast cancers are ER positive; 5% BRCA1 and 14% BRCA2 breast cancers 
are HER2 positive.[101-103, 106-108] ER & HER2 testing costs are obtained from a local 
NHS trust and included for all breast cancers. 
Endocrine therapy costs: As per NICE guidelines[47, 96], ER positive invasive breast 
cancers receive Tamoxifen 20mg/day (premenopausal)/ Anastrazole 1mg/day 
(postmenopausal) for 5 years: costed from the BNF.[91] Rates are adjusted for BRCA 
carriers, ER positivity and menopause status. 
Biphosphonate costs: 74% patients with advanced breast cancer will develop bone 
metastases and 65% patients with bone metastases are offered bisphosphonates.[47, 109, 
110] As per NICE guidelines, costs (from BNF[91]) assume that 50% patients receive oral 
clodronate & ibandronic acid, and 50% receive intravenous zoledronic acid or 
pamidronate.[47] 
Cost of Trastuzumab: For HER2 positive patients, given at 3-week intervals for 1 year or until 
disease recurrence as per NICE guidelines. Costs obtained from NICE costing report.[47] 
35% of early/locally advanced breast cancer progress to advanced breast cancer (NICE 
guidelines).[47] Recurrence rates for early/locally advanced breast cancer (from the USA 
National Surgical Adjuvant Breast and Bowel Project (NSABP)):  15.9% for node 
positive[111] and 11% for node negative[112] breast cancer: composite recurrence rate= 
12.6% (weighted for 31% node positive and 69% node negative disease). Recurrence rate 
for advanced/metastatic breast cancer is 66% (34% relapse free 5yr survival).[52] 
Follow up Costs: Includes annual mammograms and six monthly consultations. MRI scan for 
all stage 4 cancers. Costs include a progression rate of 35% from early & locally advanced to 
advanced disease,[47] and 66% relapse rate for advanced disease.[52] 
Costs for terminal care for breast cancer were derived from end-of-life costs for cancer 
patients based on a report from the National Audit Office, UK.[93] In line with NICE 
recommendations future healthcare costs not associated with breast cancer were not 
considered.[25] 
Chemoprevention (sensitivity analysis): Tamoxifen/Raloxifene for 5 years[19, 23], from 
BNF[91] 
 
†For more detailed explanation, see Supplementary Table 2, available online. 
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Table 3: Model outcomes for costs, life years and quality adjusted life years (QALYs), undiscounted 
and discounted 
 
 
Population Screening 
  Undiscounted Discounted 
Probability Cost, £ 
Life 
years QALYs  Cost, £ 
Life 
years QALYs  
              
A. PS, carrier, RRM, RRSO, no 
OC/BC 0.0068 5197 53.00 53.00 3819 23.40 23.40 
B. PS, carrier, RRM, RRSO, OC 0.0001 30343 38.20 37.22 13550 19.75 19.39 
C. PS, carrier, RRM, RRSO, BC 0.0002 27936 46.92 45.63 28013 21.48 20.74 
D. PS, carrier, RRM, no RRSO,no 
OC/BC 0.0038 2976 53.00 53.00 2766 23.40 23.40 
E. PS, carrier, RRM, no RRSO, OC 0.0017 28121 38.20 37.22 12497 19.75 19.39 
F. PS, carrier, RRM, no RRSO, BC 0.0003 25715 46.92 45.63 26960 21.48 20.74 
G. PS, carrier, no RRM, RRSO, no 
OC/BC 0.0047 8297 53.00 53.00 5025 23.40 23.40 
H. PS, carrier, no RRM, RRSO, OC 0.0001 33442 38.20 37.22 16256 19.75 19.39 
I. PS, carrier, no RRM, RRSO, BC 0.0017 31036 46.92 45.63 29219 21.48 20.74 
J. PS, carrier, no RRM, no RRSO, 
no OC/BC 0.0009 6075 53.00 53.00 3972 23.40 23.40 
K. PS, carrier, no RRM, no RRSO, 
OC 0.0016 31221 38.20 37.22 13703 19.75 19.39 
L. PS, carrier, no RRM, no RRSO, 
BC 0.0028 28814 46.92 45.63 28166 21.48 20.74 
M. PS, non-carrier, no OC/BC 0.8355 423 53.00 53.00 213 23.40 23.40 
N. PS, non-carrier, OC 0.0181 25568 38.63 37.83 9274 19.99 19.72 
O. PS, non-carrier, BC 0.1219 24616 49.16 47.87 8868 22.50 22.05 
Family History Screening 1.0000             
P. FH pos, carrier, RRM, RRSO, 
no OC/BC 0.0032 5197 53.0000 53.0000 3819 23.3988 23.3988 
Q. FH pos, carrier, RRM, RRSO, 
OC 0.00004 30343 38.2031 37.2150 13550 19.7536 19.3902 
R. FH pos, carrier, RRM, RRSO, 
BC 0.0001 27936 46.9236 45.6273 28013 21.4791 20.7432 
S. FH pos, carrier, RRM, no 
RRSO, no OC/BC 0.0018 2976 53.0000 53.0000 2766 23.3988 23.3988 
T. FH pos, carrier, RRM, no 
RRSO, OC 0.0008 28121 38.2031 37.2150 12497 19.7536 19.3902 
U. FH pos, carrier, RRM, no 
RRSO, BC 0.0001 25715 46.9236 45.6273 26960 21.4791 20.7432 
V. FH pos, carrier, no RRM, 
RRSO, no OC/BC 0.0022 8297 53.0000 53.0000 5025 23.3988 23.3988 
W. FH pos, carrier, no RRM, 
RRSO, OC 0.0000 33442 38.2031 37.2150 14756 19.7536 19.3902 
X. FH pos, carrier, no RRM, 
RRSO, BC 0.0008 31036 46.9236 45.6273 29219 21.4791 20.7432 
Y. FH pos, carrier, no RRM, no 
RRSO, no OC/BC 0.0004 6075 53.0000 53.0000 3972 23.3988 23.3988 
Z. FH pos, carrier, no RRM, no 
RRSO, OC 0.0007 31221 38.2031 37.2150 13703 19.7536 19.3902 
AA. FH pos, carrier, no RRM, no 
RRSO, BC 0.0013 28814 46.9236 45.6273 28166 21.4791 20.7432 
AB. FH pos, non-carrier, no 
OC/BC 0.0961 423 53.0000 53.0000 213 23.3988 23.3988 
AC. FH pos, non-carrier,  OC 0.0021 25568 38.6324 37.8321 9274 19.9915 19.7169 
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AD. FH pos, non-carrier, BC 0.0140 24616 49.1623 47.8660 8868 22.4951 22.0482 
AE. FH neg, carrier, no OC/BC 0.0030 330 53.0000 53.0000 120 23.3988 23.3988 
AF. FH neg, carrier, OC 0.0053 25475 38.2031 37.2150 9851 19.7536 19.3902 
AG. FH neg, carrier, BC 0.0095 23069 46.9236 45.6273 24314 21.4791 20.7432 
AH. FH neg, non-carrier, no 
OC/BC 0.7352 330 53.0000 53.0000 120 23.3988 23.3988 
AI. FH neg, non-carrier, OC 0.0159 25475 38.6324 37.8321 9182 19.9915 19.7169 
AJ. FH neg, non-carrier, BC 0.1073 24524 49.1623 47.8660 8775 22.4951 22.0482 
Average population screening  0.1484* 4156 52.1912 52.0088 1677 23.2049 23.1406 
Average family history screening  0.1587* 4233 52.1016 51.9078 1741 23.1799 23.1096 
Incremental (difference) -0.0096 -77 0.090 0.101 -64 0.025 0.031 
Cost per quality adjusted life year   -767     -2079     
Total population screening effect 837† -4467529 5166 5827 -3718526 1442 1789 
Jewish population screened 81,224             
 
* Cancer incidence; †Reduction in total number of cancer cases 
BC- Breast Cancer, FH- family history, neg- negative, OC- ovarian cancer, pos- positive, PS- population 
screening, QALY- quality adjusted life year, RRSO- risk reducing salpingo-oophorectomy, RRM –risk reducing 
mastectomy 
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Figure-1: Decision Model Structure. The upper part of the model structure reflects a 
population-based approach to BRCA testing and the lower part of the model depicts a FH-
based approach. Each decision point in the model is called a ‘node’ and each path 
extending from a node is called a decision ‘branch’. Each branch represents a mutually 
exclusive course or outcome. Each decision is given a probability (probabilities ‘p1 to p14’ 
used in the model are explained in Table1) highlighted in a white box along the decision 
branch. Values for each outcome are calculated. Cancer incidence was estimated by 
summing the probabilities of pathways ending in ovarian or breast cancer. Final outcomes 
(blue boxes on the right of the figure) of each path include development of breast cancer 
(BC), ovarian cancer (OC) and no breast/ovarian cancer (no OC or BC).  BC- Breast Cancer, 
OC-Ovarian Cancer; No OC or BC- No Ovarian Cancer or Breast Cancer developed., RRSO 
–Risk reducing salpingo-oophorectomy; RRM – Risk reducing mastectomy 
 
 
 
Figure 2: Deterministic Sensitivity Analysis for model probabilities. One-way sensitivity 
analysis for all probabilities in terms of ICER of Population-based screening compared to a 
FH-based approach for BRCA testing. X-axis: Incremental cost-effectiveness ratio (ICER): 
Cost (£) per quality adjusted life year (QALY) (discounted). Y-axis: Probability parameters in 
the model. The model is run at both lower and upper values/limits of the 95% confidence 
interval or range of all probability parameters given in Table 1. ‘High value’ represents 
outcomes for upper limit and ‘Low value’ represents outcomes for lower limit of the 
probability parameter. Outcomes to the left of the midline ‘0’ value on the X-axis indicate that 
the model is cost saving. RRM- Risk reducing mastectomy; FH – Family History; FH- family 
history, neg- negative, pos- positive, RRSO –Risk reducing salpingo-oophorectomy; RRM – 
Risk reducing mastectomy. 
  
 
 
 
 
 
Figure 3: Deterministic Sensitivity Analysis for model Costs & Utilities. One-way 
sensitivity analysis for all model costs and utility-score parameters in terms of ICER of 
Population-based screening compared to a FH-based approach for BRCA testing. X-axis: 
Incremental cost-effectiveness ratio (ICER): Cost (£s) per quality adjusted life year (QALY) 
(discounted). Y-axis: Cost and Utility-score parameters in the model.  The model is run at 
both lower and upper values/limits of the cost and utility-score parameters given in Table 2. 
‘High value’ represents outcomes for upper limit and ‘Low value’ represents outcomes for 
lower limit of these parameters. Outcomes to the left of the midline ‘0’ value on the X-axis 
indicate that the model is cost saving. This analysis suggests that variation in costs and 
utility scores do not statistically significantly affect model outcomes. BC- breast cancer, FH- 
family history, neg- negative, OC- ovarian cancer, pos- positive, RRSO –Risk reducing 
salpingo-oophorectomy; RRM – Risk reducing mastectomy 
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Figure-4: Cost-effectiveness acceptability curve. Probabilistic sensitivity analysis in 
which all model parameters/variables are varied simultaneously across their distributions to 
further explore model uncertainty.  X-axis: Incremental cost-effectiveness ratio (ICER) in 
terms of Cost (£s)/QALY; Y-axis: Proportion of simulations. The results of 1000 simulations 
were plotted on a cost-effectiveness acceptability curve showing the proportion of 
simulations (Y-axis) that indicated that the intervention was cost-effective at different 
willingness to pay thresholds (X-axis). The solid red line marks the proportion of simulations 
found to be cost-effective at the £20,000 threshold used by NICE. 94% simulations are cost 
effective in this analysis. 
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